In the past few weeks, we have learned of several promising new coronavirus treatments, including Redcyvir, which will become the standard treatment for COVID-19 cases, according tomedia BGR. But the drugs that kill coronavirus have yet to emerge, so these promising drugs will only reduce the severity of the disease and may prevent life-threatening complications. Who confirmed this this week, saying several of the most promising drugs are still being studied.
“We do have some treatments that seem to limit the severity or duration of the disease in very early studies, but we don’t have anything that can kill or prevent the virus,” WHO spokeswoman Margaret Harris said in a press release. “We do have potentially positive data coming out, but we need to see more data to be 100 percent sure that we can say this treatment is better than that treatment.” “
WHO officials did not specify the names of any promising drugs mentioned in the statement, saying more research was needed and planned. The group announced a large-scale trial nearly two months ago, but the conclusions of the Unity trial study have not yet been published. The trial focused on four different therapies, including a combination of Redcivir, hydroxychloroquine/chloroquine, Lofinavir-Litonavir (Creech) and Lopinawe-Litonavir/interferon beta-1b.
Studies in the United States have shown that Redcivir can reduce recovery time from 15 days to 11 days on average, and note that the drug does not reduce mortality and may need to be treated with other medications. Other studies have shown that hydroxychloroquine does not have the desired effect, leading to heart complications that can endanger the patient’s life.
Creech has been shown to be effective when used in combination with two other drugs, including an antiviral drug (libavirin) and a treatment drug for multiple sclerosis (interferon beta-1b). A study from Hong Kong, China, showed that the three drug combinations reduced recovery time to seven days, compared with 12 days in the control group. In other words, while WHO is not yet ready to confirm the name of the promising new coronavirus treatment currently under study, it appears that at least two of the first four drug combinations included in the Solidarity study have been shown to be effective in COVID-19 treatment.
In addition, there are growing reports that several pharmaceutical companies are developing artificial antibodies that may act like resonator plasma therapy. Anecdotal evidence suggests that plasma during recovery can play a role in helping in severe COVID-19 cases. In addition, a growing body of research suggests that new coronaviruses can cause blood clots, while blood thinners can reduce the risk of complications. It is not clear whether these drugs are also on the WHO list.
Harris also addressed the issue of vaccines, noting that, overall, the new coronavirus is “a very tricky virus” and “it’s hard to produce a vaccine to fight.”
As of mid-March, more than 115 vaccine candidates were in progress, several of which were already in Phase 1 or Phase 2 trials. WHO said earlier that a vaccine could be developed within 12 months. Dr. Anthony Fauci, America’s top infectious disease expert, said a vaccine that, if all goes well, could be available in early 2021.